BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
See today's BioWorld
Home
» South Korea's JW Pharma out-licensed atopic dermatitis drug in $402M agreement
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
South Korea's JW Pharma out-licensed atopic dermatitis drug in $402M agreement
Sep. 6, 2018
By
Elise Mak
No Comments
HONG KONG – South Korea's JW Pharmaceutical Corp. out-licensed its atopic dermatitis candidate, JW-1601, to Danish medical dermatologist Leo Pharma A/S, which has rights to develop and commercialize the drug worldwide, except in South Korea.
BioWorld